Key result
Percutaneous transseptal mechanical aspiration achieves ~86% technical success in prohibitive-risk mitral valve endocarditis.
Why the study?
Surgery is the standard of care for mitral valve infective endocarditis with large vegetations or refractory sepsis, but 25-30% of patients are at prohibitive surgical risk. Percutaneous transseptal mechanical aspiration has emerged as a minimally invasive salvage strategy requiring comprehensive evaluation.
Does percutaneous transseptal mechanical aspiration (PTMA) debulking achieve high technical success and acceptable 30-day mortality and stroke rates in prohibitive-surgical-risk patients with native or prosthetic mitral valve infective endocarditis?
Meta-Analysis (n=242)
Yes
Does percutaneous transseptal mechanical aspiration (PTMA) debulking achieve high technical success and acceptable 30-day mortality and stroke rates in prohibitive-surgical-risk patients with native or prosthetic mitral valve infective endocarditis?
Percutaneous transseptal mechanical aspiration (PTMA) achieves an 86.4% technical debulking success rate and 74.1% 1-year survival in prohibitive-surgical-risk mitral valve endocarditis, with cerebral embolic protection devices reducing stroke risk from 14.9% to 3.8%.
Answers are grounded in this paper and cite their sources.
May support salvage aspiration in prohibitive-risk mitral endocarditis; leaves open need for prospective trials to confirm outcomes.
Background: Left-sided infective endocarditis (IE) involving native or prosthetic mitral valves carries substantial morbidity and mortality. Surgery remains the guideline-directed standard of care for large vegetations (>10 mm) with embolic risk or refractory sepsis. However, 25–30% of patients are deemed at prohibitive surgical risk due to severe comorbidities, advanced heart failure, or previous cardiac operations. Percutaneous Transseptal Mechanical Aspiration (PTMA) using large-bore suction catheters (e.g., AngioVac, AlphaVac, Penumbra Indigo CAT RX/Lightning) has emerged as a novel, minimally invasive salvage strategy. Methods: Following PRISMA guidelines, a systematic review and meta-analysis was conducted across MEDLINE, Embase, Cochrane CENTRAL, Scopus, and Web of Science. Studiesevaluating PTMA for native or prosthetic mitral valve IE in prohibitive-risk patients were included. Primary outcomes were technical success (≥ 70% vegetation volume reduction without structural valve damage) and 30-day all-cause mortality. Secondary outcomes included multimodal cerebral embolic protection device (CEPD) utilization, severe iatrogenic mitral regurgitation (MR), stroke, and 1-year valve preservation. Results: Analysis of 18 observational studies and multi-center registries comprising 242 prohibitive-risk patients (mean STS score 18.4 ± 6.2%; EuroSCORE II 22.1 ± 7.5%) demonstrated a pooled technical success rate of 86.4% (95% CI: 80.1–91.0%; I^2 = 34.2%). Concurrent CEPD deployment (Sentinel or TriGuard) occurred in 64.5% of cases and was associated with a significant reduction in clinical stroke (3.8% with CEPD vs. 14.9% without; p = 0.002). Pooled 30-day mortality was 12.8% (95% CI: 8.9–18.0%), and 1-year survival was 74.1% (95% CI: 67.2–80.0%). De novo severe MR occurred in 4.1% of cases, primarily limited to fixed-diameter cannulas in native leaflets. Conclusions: PTMA via transseptal access represents a feasible, highly effective, and life-saving source control strategy for native and prosthetic mitral valve IE in prohibitive-risk candidates. Routine integration of CEPD, combined transesophageal echocardiography (TEE) and intracardiac echocardiography (ICE) fusion imaging, and expandable soft-tip funnel cannulas significantly enhance procedural safety and long-term valve preservation
No takes yet. Share an insight, caveat, or question.
Camilo Fernández Bravo (2026) conducted a meta-analysis in Native or prosthetic mitral valve infective endocarditis (n=242). Percutaneous Transseptal Mechanical Aspiration (PTMA) was evaluated on Technical success (≥70% vegetation volume reduction without structural valve damage) (95% CI 80.1-91.0). Percutaneous transseptal mechanical aspiration achieved a pooled technical success rate of 86.4% and 12.8% 30-day mortality in prohibitive-risk mitral valve endocarditis.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: